Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
NCT06300697 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200
Last updated 2025-11-25
Summary
This study will explore potential links between atopic dermatitis and food allergy. This information will be useful to determine atopic dermatitis and food allergy share unique biochemical or genetic identifiers useful for diagnosing and treatments in the future.
This is a mechanistic study consisting of obtaining blood and skin samples from participants at baseline. Individuals may also undergo a clinically indicated oral food challenge and have blood and skin samples collected at various times during the oral food challenge. This study will create a molecular map of the pathology of atopic dermatitis and food allergy. This information will be deployed to evaluate the hypothesis that atopic dermatitis and food allergy share unique genetic transcriptional signals in which the study team can then further analyze pathological pathways and cell types.
Conditions
- Atopic Dermatitis
- Food Allergy
- Healthy
Interventions
- OTHER
-
Data and biospecimen collection
Enrolled participants will have health-related information and blood specimens collected.
- OTHER
-
Skin biopsies
Participants will be asked to provide one or two skin biopsies (days 1 and 2) from the forearm, unless the participant is a healthy child (no food allergy and no atopic dermatitis), in which case there will be no skin biopsy.
- OTHER
-
Oral Food Challenge (OFC) procedures
Participants will have the choice of consenting to an OFC (approximately 2-4 hours) to peanut, tree nut, egg, milk, or sesame. If there is no allergy history, the study team will conduct an oral food challenge to one of the choices. The OFC will occur in the clinical research area. and done the same as a clinical care OFC. A transepidermal water loss monitor will be applied to participant's arm with a sticky pad and will stay on the arm for the challenge. Food doses will be given in small amounts that increase in size up to a defined single serving of the food based upon the participants age/size. The OFC will proceed until a full dose is consumed without symptoms, or until anaphylaxis occurs. Depending upon the participant's reaction to the oral food challenge, the participant may be requested to return the next day for a research visit that would take less than an hour. The 24-hour post oral food challenge visit will include an interview to assess condition and a blood sample.
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Chase Schuler, MD · University of Michigan
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 10 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-02-15
- Primary Completion
- 2027-03-31
- Completion
- 2027-03-31
Countries
- United States
Study Locations
More Related Trials
-
Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens
NCT00557284 ·Status: COMPLETED ·Phase: PHASE4
-
Assessment of Clinical, Biological and Biometrological Paramaters in Adult Subjects Suffering From AD
NCT05639738 ·Status: TERMINATED ·Phase: NA
-
Maternal Key Nutritional Factors and Offspring's Atopic Dermatitis (MKNFOAD)
NCT02889081 ·Status: COMPLETED
-
Study of Immunoadsorption to Treat Severe Atopical Dermatitis Associated With Excessively High Serum IgE Levels
NCT00616096 ·Status: COMPLETED ·Phase: NA
-
Effects of Treatments on Atopic Dermatitis
NCT01631617 ·Status: RECRUITING ·Phase: PHASE2
-
Skin Microbial Ecology in Atopic Dermatitis
NCT04170244 ·Status: RECRUITING
-
Short-term Topical Application to Prevent Atopic Dermatitis
NCT03871998 ·Status: COMPLETED ·Phase: NA
-
Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy
NCT03089476 ·Status: WITHDRAWN ·Phase: NA
-
Dietary Intervention on Atopy
NCT06547372 ·Status: RECRUITING ·Phase: NA
-
Assessment of Clinical, Biological and Biometrological Parameters in Adults Subjects With Atopic Dermatitis
NCT07017348 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis
NCT03351777 ·Status: UNKNOWN ·Phase: PHASE2
-
Prenatal Exposure to Emerging Contaminants and Children's Atopic Dermatitis
NCT06316609 ·Status: ACTIVE_NOT_RECRUITING
-
Systems Biology of Early Atopy
NCT04798079 ·Status: ACTIVE_NOT_RECRUITING
-
Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis
NCT01782703 ·Status: ACTIVE_NOT_RECRUITING
-
Ethnic Differences in Mechanisms of Action of Dupilumab
NCT05268107 ·Status: RECRUITING ·Phase: PHASE4
-
Disease Trajectories and Anti-cytokine Response Signatures in Atopic Dermatitis and Psoriasis
NCT03361215 ·Status: RECRUITING
-
Collection of Clinical and Instrumental Data in Adult Subjects Suffering From Atopic Dermatitis
NCT04553224 ·Status: COMPLETED ·Phase: NA
-
Open-Label,Singel Center Study of Alefacept in Patients With Atopic Dermatitis
NCT00376129 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab
NCT05602207 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment of AD With IgE Specific Immunoadsorption (IGEIAAD)
NCT02365246 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis
NCT03689829 ·Status: TERMINATED ·Phase: PHASE1
-
Histamine Pharmacogenetics in Children With Atopic Dermatitis
NCT00277433 ·Status: COMPLETED
-
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
NCT03607422 ·Status: COMPLETED ·Phase: PHASE3
-
Dose-Finding Study of M516102 in the Treatment of Pruritus Associated With Atopic Dermatitis
NCT00980629 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)
NCT03849716 ·Status: ACTIVE_NOT_RECRUITING